Biologics use in Ankylosing Spondylitis

Speciality: Rheumatology

Description:

A warm welcome to all the medical professionals in this interesting session on biologics use in ankylosing spondylitis

Biologics are a class of medications that have transformed the treatment landscape for ankylosing spondylitis (AS), a chronic inflammatory disease affecting the spine and joints. These drugs are designed to target specific components of the immune system, particularly proteins involved in inflammation, such as tumor necrosis factor (TNF) and interleukins. By inhibiting these pathways, biologics help reduce inflammation, alleviate pain, and improve mobility in AS patients.

The most commonly used biologics for ankylosing spondylitis include TNF inhibitors like etanercept, infliximab, and adalimumab. Clinical studies have demonstrated that these medications can significantly improve symptoms, slow disease progression, and enhance quality of life. Patients often report reduced stiffness and increased physical function after starting treatment with biologics.

In addition to TNF inhibitors, newer biologics targeting interleukin pathways, such as IL-17 and IL-23, are also gaining traction. These include drugs like secukinumab and guselkumab, which have shown promising results in managing AS. They offer alternative treatment options for patients who do not respond adequately to TNF inhibitors or experience side effects.

Therefore, get an overall knowledge of biologics use in ankylosing spondylitis. Listen to the webinar, grab the shared knowledge, and follow Hidoc for more such interesting webinar sessions.
 

See More Webinars @ Hidoc Webinars